Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

Four months after giving Eli Lilly’s Alzheimer’s disease treatment  a thumbs down, Europe’s Committee for Medicinal Products ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug, Kisunla, one step closer to European market entry.

The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side ...

An expert committee recommended that the drug be offered to a narrow group of patients with early-stage Alzheimer’s ...

Roche is focusing on early diagnosis of Alzheimer's disease and will soon release its first blood-based biomarker for the ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...

UCSF researchers found the cancer drugs letrozole and irinotecan may reverse Alzheimer's effects, reducing tau protein clumps ...

Leqembi is the first FDA-approved drug shown to slow the progression of early-stage Alzheimer’s. Medi-Cal can cover Leqembi ...